drugset / Trial / NCT02770365

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365

Phase 3 Completed 695 enrolled Padagis LLC Impax Laboratories, LLC · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.

Timeline

Start
2016-05
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified

Indications

No indication recorded.